A new meningococcal vaccine developed by scientists at the St. Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical and Biological Agency (FMBA) will be available in Russia in 2027. Currently in clinical trials, the vaccine’s registration documents are expected to be submitted by the end of 2025, according to the FMBA’s Telegram channel.
In April, FMBA head Veronika Skvortsova confirmed that the vaccine is in Phase 1 clinical trials. The formulation features a unique composition, including serotypes A, C, Y, W, and recombinant component B, which is known to cause severe sepsis in 30% of infection cases and is the most prevalent in Russia.
Aleksandr Rumyantsev, a member of the Duma Committee on Health Protection, emphasized the vaccine’s importance. He noted that State Duma deputies plan to develop amendments by the end of 2026 to include meningococcal vaccination in the National Vaccination Calendar.
Rumyantsev highlighted WHO recommendations, stating that five new vaccines—including the meningococcal vaccine—are prioritized for inclusion in the National Vaccination Calendar. “We aim to implement relevant legislative initiatives this year to facilitate this process, aligning with government commitments,” he said.
The parliamentarian also pointed out that many countries have already adopted WHO guidance, while Russia has lagged behind due to the absence of a domestically developed vaccine.